Chemotherapy is used across nearly every stage of cancer, from stage I through stage IV. The goals shift dramatically depending on how advanced the disease is: in early stages, chemotherapy aims to cure; in later stages, it may focus on extending life or relieving symptoms. The one stage where chemotherapy is almost never used is stage 0, where abnormal cells haven’t yet invaded surrounding tissue.
Stage 0: Chemotherapy Is Not Needed
Stage 0 cancers, sometimes called “in situ” cancers, are collections of abnormal cells that haven’t spread beyond their original location. Because these cells pose little immediate threat, chemotherapy isn’t part of the treatment plan. In breast cancer, for example, stage 0 ductal carcinoma in situ (DCIS) is treated with surgery and sometimes hormone-blocking therapy, but chemotherapy is listed as “none” in national treatment guidelines. The same principle applies to most other cancer types at this earliest stage.
Stages I and II: Preventing Recurrence
Chemotherapy enters the picture at stage I, though not everyone with early-stage cancer needs it. The decision depends on tumor size, how fast the cancer is growing, and specific biological features of the tumor itself. In breast cancer, chemotherapy after surgery is sometimes recommended once a tumor is larger than about half a centimeter. For smaller tumors, it may still be considered if the cancer is fast-growing or lacks hormone receptors that would make it responsive to other treatments.
At stage II, chemotherapy becomes more common. It can be given before surgery (called neoadjuvant chemotherapy) to shrink a large tumor, sometimes enough to allow a less extensive operation. It can also be given after surgery (adjuvant chemotherapy) to destroy any cancer cells that may have escaped the primary tumor but are too small to detect on scans. Both approaches produce similar long-term survival rates, so the choice often depends on the clinical situation.
For certain early-stage cancers, genomic tests help determine whether chemotherapy will actually help. In hormone-receptor-positive, HER2-negative breast cancer, a test called Oncotype DX assigns a recurrence score. Patients scoring below 18 generally see no benefit from adding chemotherapy to hormone therapy. Those scoring above 30 have a distant recurrence risk around 30.5% and clearly benefit from chemotherapy. The intermediate range remains less clear-cut, though younger patients (45 and under) with scores of 18 or higher do appear to gain a survival advantage from chemotherapy.
Stage III: A Standard Part of Treatment
By stage III, cancer has typically grown larger or spread to nearby lymph nodes but hasn’t reached distant organs. Chemotherapy is a routine part of treatment at this stage for most cancer types. Neoadjuvant chemotherapy is especially useful here because it can downsize tumors that might otherwise be difficult to remove surgically, and it gives doctors early information about how well the cancer responds to treatment. That response helps guide what therapies are used afterward.
For some stage III cancers where surgery isn’t feasible, chemotherapy may be combined with radiation as the primary treatment. Locally advanced esophageal cancer is one example: when a tumor can’t be surgically removed, concurrent chemotherapy and radiation is the standard of care recommended by national guidelines. This combined approach treats the tumor directly while also addressing any microscopic disease nearby.
Stage IV: Extending Life and Easing Symptoms
Stage IV means cancer has spread to distant parts of the body. In most solid tumors, chemotherapy at this stage is not curative. Instead, it serves two distinct purposes that are worth understanding separately.
The first is life extension. For many metastatic cancers, modern chemotherapy regimens can add meaningful time. Metastatic colorectal cancer patients often survive beyond 24 months with treatment, and about 10% live past five years. Metastatic breast and prostate cancer patients frequently survive years, sometimes past a decade. These aren’t cures, but they represent significant stretches of life that wouldn’t be possible without treatment.
The second purpose is symptom relief. When a tumor is pressing on nerves, blocking an organ, or causing pain, chemotherapy can shrink it enough to restore comfort and function. In this role, the primary goal isn’t necessarily adding months of life but improving the quality of the time remaining.
Blood Cancers Follow Different Rules
Leukemia, lymphoma, and other blood cancers don’t follow the same staging system as solid tumors, and chemotherapy plays a different role. Traditional stage numbering (I through IV) matters less in directing treatment. Instead, doctors classify these cancers as “limited” or “advanced” based on how widespread the disease is, along with various prognostic factors like age, blood counts, and specific genetic markers.
Chemotherapy is often the backbone of treatment for blood cancers at every stage, because surgery can’t remove a cancer that lives in the blood, bone marrow, or lymphatic system. Even limited-stage lymphoma typically involves chemotherapy, sometimes combined with radiation. The staging system helps predict outcomes and intensity of treatment rather than determining whether chemotherapy is used at all.
Targeted Therapies Are Changing the Picture
For some cancers, newer targeted therapies or immunotherapies are partially replacing traditional chemotherapy. In non-small cell lung cancer with certain genetic mutations, targeted pills can be more effective and less toxic than chemotherapy. In HER2-positive metastatic breast cancer, adding targeted drugs to chemotherapy has extended survival by more than 15 months compared to chemotherapy with just one targeted drug. For patients whose tumors have specific molecular profiles, matched targeted treatments have shown progression-free survival of 9.1 months versus 2.8 months with chemotherapy alone.
That said, these therapies only work for patients whose tumors carry the right molecular targets, which remains a minority. For most patients with advanced cancer, chemotherapy still plays a central role, often alongside these newer treatments rather than being fully replaced by them.
What Determines If You’re Healthy Enough
Stage isn’t the only factor. Your overall physical condition matters just as much. Oncologists use a scale called the ECOG performance status, which ranges from 0 (fully active with no limitations) to 4 (completely bedridden). Professional guidelines recommend against chemotherapy for patients with solid tumors who score 3 or higher, meaning they’re confined to a bed or chair for more than half their waking hours. At that point, chemotherapy is unlikely to help and may cause more harm than benefit.
A person who scores 0, 1, or 2 is generally considered well enough to tolerate treatment. This means a stage IV patient in good physical shape may still be a strong candidate for chemotherapy, while a stage II patient with serious other health problems might not be.
What a Typical Course Looks Like
A standard course of chemotherapy lasts three to six months, though it can be shorter or longer depending on the situation. Most patients go through four to eight treatment cycles, with each cycle spaced one to four weeks apart. The gaps between cycles give your body time to recover from side effects before the next round.
Curative chemotherapy (stages I through III) tends to follow a set number of cycles with a defined endpoint. Palliative or life-extending chemotherapy for stage IV disease may continue for longer, sometimes indefinitely, as long as it’s working and the patient tolerates it. Treatment plans are reassessed regularly with imaging scans to see whether the cancer is responding.